Kif18a inhibitor pipeline

Author: hiue

August undefined, 2024

WebKinase-like protein 18A (KIF18A) is a mitotic kinesin motor protein that regulates chromosome positioning during cell division and is overexpressed in a subset of human cancers. 1-3. Preclinical studies of KIF18A gene inactivation suggest its function can be … Web7 mrt. 2024 · Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline March 7, 2024 Financing led by founding investors Polaris Partners and ARCH Venture …

Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor …

Web28 feb. 2024 · KIF18A is accumulated at the plus ends of microtubules and regulates its stability 20. In addition, in the pre-anaphase state of the cell cycle, KIF18A regulates mitotic chromosome alignment by inhibiting the movement of kinetochores. These pieces of evidence confirmed that KIF18A plays an important role in the regulation of motility and … Web6 apr. 2024 · Notably, the expression of kinesin-8 is often dysregulated in cancer and therefore may play an important role in that process. Interestingly, overexpression of KIF18A was reported to promote tumour formation, invasion and metastasis in colorectal cancer, while its knockdown triggered proliferation decrease in cancer cell lines, altogether … lw.ldyjh.com

Volastra Therapeutics to Present Preclinical Data from KIF18A …

Web2 jun. 2024 · Background: KIF18A is a kinesin assisting chromosome congression and alignment during mitosis. It is nonessential in normal, euploid cell division but essential for a subset of aneuploid cancer cells with high chromosomal instability (CIN-high). KIF18A … Web29 sep. 2024 · KIF18A is a protein that helps usher cells through mitosis by helping to align chromosomes. Normal cells can divide without KIF18A, but cells high in CIN have increased mitotic adaptation and errors, and are therefore, we believe, more dependent on KIF18A … Web19 nov. 2024 · The KIF18A gene belongs to the Kinesin-8 subfamily and is a plus-end-directed motor. KIF18A is believed to influence dynamics at the plus end of kinetochore microtubules to control correct chromosome positioning and spindle tension. lwl format

Small molecule screen to identify mitotic kinesin KIF18A inhibitors

Discovery of potent, orally active KIF18A inhibitors targeting CIN …

WebTwo known KIF18A inhibitors exist; however, their function is either limited (BTB-1) or the efficacy remains to be publicly validated (Amgen). In this thesis, a screening protocol involving fluorescent-based live cell imaging was formulated to test several small molecule compounds that were suspected to have compatibilities with a binding site on KIF18A. Web9 sep. 2024 · KIF18A is a mitotic kinesin that regulates chromosome alignment during cell division. Leveraging its proprietary CINtech platform, Volastra discovered that CIN-high cancer cells are more dependent on chromosome alignment machinery like KIF18A and … lwl fiberWeb20 feb. 2015 · Using BTB-1, the first identified Kif18A inhibitor, as a lead compound, we synthesized a collection of derivatives. We demonstrate that some of the synthesized derivatives potently inhibited the ATPase activity of Kif18A with a half maximal … lwl fred trainer

"Web9 sep. 2024 · Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference September 9, 2024 Treatment with KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in multiple tumor... Load More In The News " - Kif18a inhibitor pipeline

Kif18a inhibitor pipeline

Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor …

WebUsing BTB-1, the first identified Kif18A inhibitor, as a lead compound, we synthesized a collection of derivatives. We demonstrate that some of the synthesized derivatives potently inhibited the ATPase activity of Kif18A with a half maximal inhibitory concentration (IC …

Did you know?

Web28 mei 2024 · TPS5600. Background: KIF18A is a mitotic kinesin motor protein that regulates chromosome positioning during cell division and is overexpressed in a subset of human cancers. TP53 mutant unstable aneuploid cancer cells with chromosomal … Web7 mrt. 2024 · "We are excited to add sovilnesib to our growing pipeline of CIN-targeted therapeutics which includes our own KIF18A inhibitor, VLS-1488," said Charles Hugh-Jones, Chief Executive Officer at Volastra.

Web7 mrt. 2024 · Volastra Therapeutics announced Tuesday it has in-licensed Amgen’s Phase I candidate sovilnesib, a KIF18A inhibitor being studied for high-grade ovarian cancer, triple-negative breast cancer and other solid tumors. Concurrently, the New York-based … WebTwo known KIF18A inhibitors exist; however, their function is either limited (BTB-1) or the efficacy remains to be publicly validated (Amgen). In this thesis, a screening protocol involving fluorescent-based live cell imaging was formulated to test several small …

Web15 apr. 2024 · When SDX-7320 was administered as a monotherapy at a dose of 8 mg/kg, it yielded a tumor growth inhibition rate (TGI) of 49%. Single-agent palbociclib, delivered at 20 mg/kg, elicited a TGI rate ... Web8 mrt. 2024 · Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline Category: More News Published on Wednesday, 08 March 2024 08:50 Hits: 2551 Financing led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly.

Web9 sep. 2024 · NEW YORK--(BUSINESS WIRE)-- Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability (CIN), today announced new data from its lead program, a KIF18A inhibitor, validating its therapeutic approach of synthetic lethality to induce tumor cell death.The data will be presented at the 2024 Consequences …

WebBackground: KIF18A is a kinesin assisting chromosome congression and alignment during mitosis. It is nonessential in normal, euploid cell division but essential for a subset of aneuploid cancer cells with high chromosomal instability (CIN-high). KIF18A knockdown … lwl fortbildung jugendhof vlothoWeb4 sep. 2024 · KIF18A is overexpressed in various types of cancers, including but not limited to colon, breast, lung, pancreas, prostate, bladder, head, neck, cervix, and ovarian cancers. Further, genetic deletion or knockdown or inhibition of KIF18A affects mitotic spindle … kings marine chertseyWebVLS-1488 (KIF18A inhibitor) Synthetic Lethal. IND Enabling kingsmark way goldthorpeWeb7 mrt. 2024 · Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline. Financing led by founding investors ... lwl fernimWebBTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC50 of 1.69 μM. IC 50 & Target. IC50: 1.69 μM (Kif18A) [1] In Vitro. BTB-1 blocks the motility of Kif18A in a reversible manner. BTB-1 inhibits Kif18A in an adenosine triphosphate (ATP)-competitive but microtubule-uncompetitive manner and slows down ... lwl fiber opticWeb1 nov. 2024 · To inhibit KIF18A activity, a highly specific small molecule inhibitor for KIF18A, BTB-1 was used. DCs were differentiated from mouse bone marrow (BM) cells from 6 to 7 week old C57BL/6 mice with recombinant granulocyte–macrophage colony-stimulating factor (GM-CSF). Expression of KIF18A was measured by Western blotting. lwl ethernetWeb9 sep. 2024 · KIF18A inhibitor on track to enter the clinic in 2H 2024 NEW YORK, September 9, 2024 – Volastra Therapeutics , an oncology company focused on exploiting chromosomal instability (CIN), today announced new data from its lead program, a … kings marine michigan center mi